Economic impact of introducing the injectable inactivated polio vaccine in Colombia;Impacto económico de la introducción de la vacuna inactivada inyectable contra la poliomielitis en Colombia

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 27, Issue 5, 2010, Pages 352-359

  Alvis, Nelson ^a   De La Hoz, Fernando ^b   Narváez, Javier ^b  

^a UNIVERSIDAD DE CARTAGENA   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

Colombia; Cost benefit analysis; Disabilityadjusted life years; Mass vaccination; Poliovirus vaccine, inactivated; Poliovirus vaccine, oral

Indexed keywords

COST-BENEFIT ANALYSIS; DISEASE CONTROL; DRUG; ECONOMIC IMPACT; HEALTH SERVICES; MARKOV CHAIN; VACCINATION; VACCINE; VIRAL DISEASE;

POLIOVIRUS;

EID: 77954283160     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: 10.1590/s1020-49892010000500005     Document Type: Article

References (38)

1. Progress toward global poliomyelitis eradication, 2000. Morb Mortal Wkly Rep. 2001;50(16):320-2, 331.
2. Global progress toward certifying polio eradication and laboratory containment of wild polioviruses. August 2002-August 2003. Morb Mortal Wkly Rep. 2003;52(47):1158-60.
3. Global Polio Eradication Initiative Strategic Plan, 2004. Morb Mortal Wkly Rep. 2004;53(5):107-8.
4. Dutta A. Epidemiology of poliomyelitisoptions and update. Vaccine. 2008;26(45):5767-73.
5. Bart KJ, Foulds J, Patriarca P. Global eradication of poliomyelitis: benefit-cost analysis. Bull World Health Organ. 1996;74(1):35-45.
6. Kahn MM, Ehreth J. Costs and benefits of polio eradication: along-run global perspective. Vaccine. 2003;21:702-5.
7. Musgrove P. Is polio eradication in the Americas economically justified? Bull Pan Am Health Organ. 1988;22(1):1-16.
8. Thompson KM, Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. Lancet. 2007;369(9570):1363-71.
9. Thompson KM, Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal. 2006;26(6):1423-40.
10. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Wkly Epidemiol Rec. 2003;78(28):241-52.
11. Kumate J. Cincuentenario de la vacuna Salk. Bol Med Hosp Infant Mex. 2005;62:239-41.
12. Miller MA, Sutter RW, Strebel PM, Hadler SC. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. J Am Med Assoc. 1996;276(12):967-71.
13. Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol Rec. 2006;81(15):137-44.
14. República de Colombia, Banco de la República. Series estadísticas. Tasas de cambio. Santa Fe de Bogotá: Banco de la República; 2009. Hallado en http://www.banrep. gov. co/series- estadisticas/see-ts-cam.htm. Acceso el 4 de marzo de 2010.
15. Boshell J, Peláez D, Camacho T, Castaño M, Bernal C. Programa de Erradicación de la Poliomielitis en Colombia: apoyo del laboratorio de virología, INS, 1992-1998. Biomédica. 1999;19(1):175.
16. Departamento Administrativo Nacional de Estadísticas. Proyecciones de población. Hallado en http://www.dane.gov. co/daneweb-V09/index.php? option=com-content&view=article&id=75&Itemid=72. Acceso el 16 de marzo de 2010.
17. República de Colombia, Ministerio de la Protección Social. Programa ampliado de inmunizaciones: coberturas de vacunación municipales 1998-2008. Santa Fe de Bogotá: Ministerio de Protección Social; sin año. Hallado en http://www.minproteccionsocial.gov. co/pai/Gestión.aspx. Acceso el 16 de marzo de 2010.
18. Thompson KM, Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health. 2008;98(7):1322-30.
19. Más Lago P, Ferrer H, Goyenechea A, Galindo A, Sarmiento L, Fonseca M, et al. Casos de poliomielitis paralítica asociada a la vacuna oral antipoliomielítica en Cuba (1963-2006). Rev Cubana Hig Epidemiol. 2008;46:1-14.
20. Kohler KA, Banerjee K, Hlady WG, Andrus JK, Sutter RW. Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull World Health Organ. 2002;80(3):210-6.
21. Murray CJL, López AD, eds. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston, MA: Harvard School of Public Health; 1996.
22. World Health Organization. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: WHO; 2001. Hallado en http://whqlibdoc.who.int/publications/ 2001/924154550x.pdf. Acceso el 7 de marzo de 2010.
23. Minor PD, Muir P. Enteroviruses. In: Zuckerman AJ, Banatvala JE, Pattison JR, Griffiths PD, Schoub BD, eds. Principles and practice of clinical virology. 5th ed. Chichester, UK: John Wiley & Sons; 2004. Pp. 485-6.
24. Mahadevan S, Ananthakrishnan S, Srinivasan S, Nalini P, Puri RK, Badrinath S, et al. Poliomyelitis: 20 years-the Pondicherry experience. J Trop Med Hyg. 1989;92(6):416-21.
25. Andrus JK, Strebel PM, de Quadros CA, Olive JM. Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-91. Bull World Health Organ. 1995;73(1):33-40.
26. De Oliveira LH, Struchiner CJ. Vaccineassociated paralytic poliomyelitis in Brazil, 1989-1995. Rev Panam Salud Publica. 2000;7(4):219-24.
27. Teixeira-Rocha ES, Carmo EH, Tavares-Neto J. The occurrence of vaccine-associated paralytic poliomyelitis in Brazil, 1995 to 2001. Rev Panam Salud Publica. 2005;18(1):21-4.
28. Nkowane BM, Wassilak SG, Orenstein WA, Bart KJ, Schonberger LB, Hinman AR, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. J Am Med Assoc. 1987;257(10):1335-40.
29. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis. 1992;14(2):568-79.
30. Joce R, Wood D, Brown D, Begg N. Paralytic poliomyelitis in England and Wales, 1985-91. Br Med J. 1992;305(6845):79-82.
31. Griffiths UK, Botham L, Schoub BD. The costeffectiveness of alternative polio immunization policies in South Africa. Vaccine. 2006;24(29-30):5670-8.
32. Tucker AW, Isaacs D, Burgess M. Costeffectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia. Aust N Z J Public Health. 2001;25(5):411-6.
33. Organización Panamericana de la Salud. Vigilancia de parálisis flácida aguda. Bol Sem Polio. 2006;21(48):2.
34. Grupo de Vigilancia de Inmunoprevenibles. Informe de la vigilancia de eventos de interés en salud pública: inmunoprevenibles. Santa Fe de Bogotá: Instituto Nacional de Salud; 2007. Hallado en http://www.ins.gov. co/?idcategoria=5656#. Acceso el 7 de marzo de 2010.
35. Prevots DR, Burr RK, Sutter RW, Murphy TV. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2000;49(RR-5):1-22.
36. Le Saux N, Barrowman NJ, Moore DL, Whiting S, Scheifele D, Halperin S. Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics. 2003;112(5): e348.
37. Rennels MB, Englund JA, Bernstein DI, Losonsky GA, Anderson EL, Pichichero ME, et al. Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheriatetanusacellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatr Infect Dis J. 2000;19(5):417-23.
38. Ekwueme DU, Strebel PM, Hadler SC, Meltzer MI, Allen JW, Livengood JR. Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. Arch Pediatr Adolesc Med. 2000;154(8):797-803.